



MEMORANDUM

To: All Physicians, Nurse Practitioners, & Chemistry Lab Staff, Eastern Health  
Date: October 29, 2019  
Re: New Method for Anti-Cardiolipin Antibodies (IgG & IgM) and Anti-Tissue Transglutaminase IgA (TTG)  
From: Biochemistry Department, Laboratory Medicine

---

Dear Colleagues,

This is to indicate that as of November 5, 2019, we will be introducing a new method for measuring IgG and IgM Cardiolipin Antibodies and TTG (IgA tissue Transglutaminase) Antibodies.

This new method, known as ELIA Cardiolipin IgG and IGM, uses a clinical cut-off of > 40 GPL-MPL-U/mL for positive. Results between 10 and 40 GPL-MPL-U/mL are classified as weak positive, and results < 10 is considered negative.

Patients with persistent positivity should be monitored regularly. In the absence of clinical findings, persistently high positive (interval of at 12 weeks) results indicate an increased risk for thrombosis, or pregnancy complications, and possible diagnosis of antiphospholipid syndrome (APS) in the future.

Tissue Transglutaminase TTG is the major autoantigen in Celiac disease. IgA antibodies against TTG are highly disease specific serological markers for Celiac disease and Dermatitis Herpetiformis. The new ELIA Celikey IgA TTG test uses the following reference ranges:

- Negative < 7 ELIA-U/mL
- Equivocal between 7 and 10 ELIA-U/mL
- Positive > 10 ELIA-U/mL

As there can be intermethod discrepancies for patients where continuous monitoring is required, re-establishing of baseline values is advised.

As always, please let us know of any concerns, issues or questions regarding these changes. Your feedback is greatly appreciated.

Kindest Regards,

*Ed Randell, PhD, DCC FCACB  
Division Chief & Prof  
Dept. of Lab. Med., Eastern Health Auth.  
& Faculty of Medicine, Memorial University  
Rm1J442, Biochemistry Dept.  
Health Sciences Centre, Eastern Health  
Office: 709-777-6375/Fax: 709-777-2442*